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The malaria genome encodes over 5,000 proteins and many of these have also been
proposed to be potential vaccine candidates, although few of these have been tested
clinically. RH5 is one of the leading blood-stage Plasmodium falciparum malaria vaccine
antigens and Phase I/II clinical trials of vaccines containing this antigen are currently
underway. Its likely mechanism of action is to elicit antibodies that can neutralize
merozoites by blocking their invasion of red blood cells (RBC). However, many other
antigens could also elicit neutralizing antibodies against the merozoite, and most of
these have never been compared directly to RH5. The objective of this study was
to compare a range of blood-stage antigens to RH5, to identify any antigens that
outperform or synergize with anti-RH5 antibodies. We selected 55 gene products,
covering 15 candidate antigens that have been described in the literature and 40 genes
selected on the basis of bioinformatics functional prediction. We were able to make
20 protein-in-adjuvant vaccines from the original selection. Of these, S-antigen and
CyRPA robustly elicited antibodies with neutralizing properties. Anti-CyRPA IgG generally
showed additive GIA with anti-RH5 IgG, although high levels of anti-CyRPA-specific
rabbit polyclonal IgG were required to achieve 50% GIA. Our data suggest that further
vaccine antigen screening efforts are required to identify a second merozoite target with
similar antibody-susceptibility to RH5.
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INTRODUCTION
Development of a vaccine against Plasmodium falciparum malaria is a key global health priority
(1). RTS,S/AS01, the leading subunit malaria vaccine, targets the pre-erythrocytic stage of the P.
falciparum parasite’s lifecycle to deliver a short interval of moderate protection against malaria (2),
which then wanes to yield 7 year efficacy of < 10% (3). Blood-stage vaccines aim to target the
subsequent disease-causing stage of the Plasmodium life cycle and have the possibility of protecting
against disease severity, reducing blood-stage asexual parasitemia as well as transmission, while
allowing exposure to the parasite and the development of naturally-acquired immunity.
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Blood-stage vaccines can be divided into those that aim to
target the infected red blood cell (iRBC), and those that target
the merozoite (1). Most anti-merozoite vaccines aim to elicit
antibodies that bind to proteins involved in the process of red
blood cell (RBC) entry thus leading to a block in RBC invasion.
This antibody functionality can be routinely tested using the
standardized in vitro assay of growth inhibitory activity (GIA)
(4). A key challenge has been to identify antigens that are both
well-conserved between disparate strains of P. falciparum, and
sufficiently susceptible to antibody neutralization in the minute
or so between schizont egress and RBC re-invasion (5) in a way
to meaningfully impact the in vivo parasite multiplication rate. P.
falciparum reticulocyte-binding protein homolog 5 (RH5) is the
only protein to-date which has been demonstrated by multiple
independent research groups to possess these properties (6–9).
Notably, RH5 binds basigin on the surface of RBCs, forming
an interaction that is essential for productive invasion of the
RBC (10).
Phase I/II clinical trials are now underway to test the
safety, immunogenicity and efficacy of first-generation vaccines
containing the RH5 antigen (11, 12). The outcomes of these
trials will serve as an important benchmark for the field of
merozoite neutralizing vaccines. When interpreting the results
of these clinical trials and deciding how to prioritize further
research avenues, a critical question will be whether there are
additional antigens (or combinations of antigens) encoded in the
P. falciparum genome which could deliver higher efficacy than
the vaccines currently being trialed that target RH5 alone.
To address this question, we generated a list of candidate
antigens for a merozoite-neutralizing vaccine and tested their
ability to elicit functional antibodies, comparing to RH5 as the
“gold-standard” antigen. We aimed to minimize false-negatives
by adopting the following approaches. First, we used protein-
based vaccine immunization which, in contrast to genetic/nucleic
acid-based immunization approaches such as recombinant
viral vectors (7), allows for controlled administration of a
fixed dose of antigen. Second, we produced recombinant
protein which, wherever possible, represented the full-length
ectodomain of the P. falciparum protein, to minimize the
possibility of producing non-conformationally relevant protein
fragments as initially occurred with RH5 (13–15). Third,
wherever possible, rather than use Freund’s adjuvant [a strong
immunopotentiator that elicits extremely high titers of antibodies
but which can also disrupt the fold of even the most stable
proteins (16, 17)], we used AddaVaxTM, a squalene-based
adjuvant similar in composition to the clinically-approved
adjuvant MF59 R©.
Testing all 5,000 proteins encoded in the P. falciparum
genome is not feasible and so in our first panel we aimed to test
all of the proteins that have been the subject of promising vaccine
antigen reports in the literature. We then selected a second panel,
drawn from a list of 435 proteins that have been bioinformatically
predicted (18) to have a role in merozoite invasion. This was 55
proteins in all. Proteins were generated for 20 of these, and then
formulated in adjuvant for immunization into mice. The post-
immunization mouse antibodies were harvested and then tested
for activity in the GIA assay.
MATERIALS AND METHODS
Analysis of Polymorphism of Merozoite
Proteins
The raw material for this polymorphism analysis was gathered
from a range of sources [(19–22), Pf3K, 20121]. We used
sequence coverage of a gene as an initial indicator of
vaccinological suitability. In a given dataset, sequence coverage
is as defined by the number of Illumina reads that align to a
given region of the P. falciparum clone 3D7 reference genome.
Local drops in coverage can indicate divergence of an allele from
the 3D7 reference, an A-T rich region (i.e., low complexity) or
the presence of insertions/deletions. Therefore, genes with low
sequence coverage, or spikes or drops in sequence coverage,
were excluded from study. When counting single nucleotide
polymorphisms (SNPs), we only considered non-synonymous
SNPs with uniform sequence coverage and a prevalence of over
10%. This cut-off was chosen as a plausible indicator that a SNP
is under some element of balancing selection. Polymorphism was
assessed by counting the total number of non-synonymous SNPs
along the gene, as opposed to measuring SNP density. This is
because antigenic escape mutations may cluster around regions
of a protein that are proximal in the tertiary, three-dimensional
structure, but distant in the primary sequence. This simple
counting analysis is unlikely to be confounded by the underlying
base-rate SNP density across the genome, because the base rate
of non-synonymous SNPs with prevalence of >10% is extremely
low across the P. falciparum genome [(19–22), Pf3K, 20121].
Genes with more than 4,000 bp (corresponding to 1,333 amino
acids) were excluded due to the cost of producing synthetic genes
longer than 4,000 bp.
Protein Expression and Purification
Protein sequences were uploaded to the TMHMM server
(23) to predict the ectodomains of transmembrane proteins
of interest (for proteins with no transmembrane region, the
entire soluble protein sequence was used). Synthetized genes
encoding these ectodomains (GeneArt, Germany) were cloned
into a modified pENTR4 plasmid. This plasmid contains
an extended version of the cytomegalovirus promoter (24)
downstream of an N-terminal human tissue plasminogen
activator (tPA) leader sequence and cloning site encoding
“GTK” (MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGTK)
and upstream of a sequence encoding a C-terminal affinity
construct consisting of a biotin acceptor peptide (BAP)
and either a hexa-histidine tag (“BAP-6His,” final C-terminal
amino acid sequence GLNDIFEAQKIEWHEHHHHHH) or a
Strep tag (“BAP-Strep,” final C-terminal amino acid sequence
GLNDIFEAQKIEWHEWSHPQFEK) or simply a C-tag (25) with
no biotin acceptor peptide, so final C-terminal amino acid
sequence: EPEA. All genes were codon-optimized for Homo
sapiens. The only exception to the above details was the “CyRPA
(Gly KO)” construct (Figure S6), where a complete expression
plasmid using a different backbone with different signal peptide
and C-terminal tags was kindly gifted by the laboratory of G.
1Pf3K (2012). The Pf3K Project−1.0 pilot data release.
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Wright, who had produced this plasmid [Add gene plasmid
number: 50823 (26)]. Plasmids were transiently transfected into
suspension HEK293E cells (250mL typical culture volume) using
a transfection method based on that described by Durocher et al.
(27). Briefly, cells were grown in Expi293 Expression Medium
(Thermo Fisher Scientific, USA) in a rotary shaking, 37◦C and 8%
CO2, and passaged to 1× 10
6 cells/mL 24 h prior to transfection.
On the day of transfection, plasmid DNA was mixed with linear
25 kDa average molecular weight polyethylenimine (PEI) at a
1:2 mass ratio (Alfa Aesar, USA), and incubated for 20min,
before being added to the HEK293E cell culture. 4 days after
transfection, supernatants were harvested by spinning at 500
xg for 10min and supernatants clarified with a 0.22µm filter.
Proteins were purified by single-step affinity chromatography
using either a HisTrap Excel Ni-Sepharose column (GE
Healthcare, USA) and eluting in 400mM imidazole; using a C-
tag with elution into 2M MgCl2 (25); or dialysed extensively
into phosphate-buffered saline (PBS) before application to a
Streptactin Sepharose resin and elution into the supplied elution
buffer (IBA, Germany). Purified proteins were exchanged into
PBS using a 10K MWCO centrifugal filter (Millipore, UK)
and adjusted to 0.4 mg/mL. Proteins were resolved using 4–
20% SDS-PAGE gels with reduction by 2-mercaptoethanol and
visualized directly using Coomassie brilliant blue R-250 (Bio-
Rad, USA), using Precision Plus protein Unstained Standards by
BioRad (USA), or visualized by Western blot onto nitrocellulose
membranes using streptactin-HRP conjugate (IBA, Germany) as
detection reagent. PNGase treatment (NEB, USA) was performed
as per manufacturer’s instructions.
For the N-terminal apical asparagine-rich protein (AARP)
construct in Figure S3F, a construct encoding I20 to D95 was
cloned into an Escherichia coli expression plasmid with an N-
terminal 6His tag followed by a tobacco etch virus cleavage
site (amino-acid sequence ENLYFQGS). This construct was
cloned into an E. coli expression host (BL21(DE3)Star, Thermo
Fisher Scientific) and protein induced with 1mM IPTG at 37◦C
for 4 h. Clarified soluble cell lysate was subject to Nickel-ion
affinity purification (HisTrapTM Excel, GE Healthcare) following
the manufacturer’s instructions. This was followed by protease
cleavage for removal of the 6His-tag and further size-exclusion
chromatography, yielding a protein of apparent molecular weight
12 kDa.
Animal Immunization
All mouse experiments used female 6 week old BALB/c mice (n
= 4 per group). Experiments and procedures were performed
in accordance with the UK Animals (Scientific Procedures)
Act Project License (PPLs 30/2889 and PA7D20B85) and
were approved by the University of Oxford Local Ethical
Review Body. Protein (20 µg/dose) was formulated with
AddaVaxTM (Invivogen, France) or Abisco R©-100 (Isconova,
Sweden) adjuvant, and injected intramuscularly on days 0, 21,
and 42. Final serum harvest was performed on day 49. Each 100
µL dose of vaccine consisted of 50 µL protein solution at 0.4
mg/mL mixed with an equal volume of AddaVaxTM or Abisco R©-
100 adjuvant (28), and was split across both quadriceps. For Poly
(I:C), we added 50 µL of Poly(I:C) adjuvant (Invivogen, USA)
at 1 mg/mL to each dose of 20 µg protein and split doses across
both quadriceps. In the comparative assessment of AddavaxTM
and Abisco R©-100, in addition to the GIA negative control
groups in screening, we used chicken egg ovalbumin (OVA)
(Sigma Aldrich, UK). RH5 protein, used as a functional antibody
immunization control was prepared as described previously (29).
When RH5 viral vectors (7) were used as a functional antibody
immunization control, 1010 viral particles (vp) of recombinant
human adenovirus serotype 5 (AdHu5) were administered
intramuscularly on day 1 followed by 108 plaque-forming units
(pfu) of recombinant modified vaccinia virus Ankara (MVA)
intramuscularly on day 56, with serum harvested on day 70.
For rabbit and rat immunization, Freund’s adjuvant was used
to allow comparison with other studies. For S-Antigen-BAP-
Strep and AARP-BAP-Strep rabbit immunization, Zika rabbits
were injected intramuscularly by Biogenes (Germany). For Zika
rabbits, each 400 µL dose consisted of 200 µL of protein solution
at 0.5 mg/mL (100 µg dose) and 200 µL of complete Freund’s
adjuvant (day 1) or incomplete Freund’s adjuvant (days 28
and 56). For CyRPA rabbit immunization, New Zealand White
rabbits were immunized by Cambridge Research Biochemicals
(UK). For these rabbits, each 400 µL dose consisted of 200 µL
of protein solution at 0.5 mg/mL (100 µg dose) and 200 µL
AddaVaxTM adjuvant (Invivogen, France), on days 1, 28, and
56. For all rabbits the final bleed was day 63, 1 week after the
final immunization. For CyRPA rat immunization, 2 Sprague-
Dawley, and 2 Wistar rats were immunized intramuscularly by
GenScript (Hong Kong) with 50 µg of protein formulated with
complete Freund’s adjuvant (day 1) and incomplete Freund’s
adjuvant (days 28 and 56). Rat serum was harvested on day 70
and IgG purified.
IgG Purification
Serum from immunizedmice or rabbits was diluted 2:1 in protein
G binding buffer (Pierce, UK) and applied to protein G sepharose
columns. After washing twice with 3x serum volume of binding
buffer, IgG was eluted in 10mL protein G elution buffer (Pierce,
UK) and restored to neutral pH by the addition of 300µL Trizma
pH 9.0 (Sigma Aldrich, USA). Where RBC pre-depletion was
performed, 1 µg of packed 100% hematocrit RBC per 1 µg IgG
was applied to sample, incubated at room temperature (RT) with
agitation for 1 h. RBC were then pelleted by centrifugation at
1,000 xg for 5min and the supernatant removed.
Immunofluorescence Assay
Cultures of 3D7 clone P. falciparum, synchronized to contain
mainly late schizonts, were smeared onto glass slides to make
thin films. Slides were fixed in 4% paraformaldehyde, blocked
with 3% bovine serum albumin (BSA), and then probed with
protein G purified serum IgG at 20µg/mL. Secondary antibody
was Alexa FluorTM 488 goat anti-mouse IgG (H+L) at a dilution
of 1:800 (Invitrogen, UK). Slides were mounted in ProLong
Gold antifade reagent with DAPI (Life Technologies, USA).
Images were acquired using a x100 oil-immersion objective
and a cooled QICAM Fast 1,394 camera, each using the same
exposure period.
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Assay of Growth Inhibition Activity (GIA)
These were performed to the protocol of the GIA Reference
Center, NIH, USA (4). Parasites were cultured in medium
consisting of RPMI-1640 supplemented with 10% heat-
inactivated human serum, 5.94 g/L HEPES, 0.05 g/L
hypoxanthine, and 20 mg/L gentamycin. Synchronized
parasites at 0.2–0.4% parasitemia in the trophozoite stage
were grown in medium containing 20% human serum and
40 mg/L gentamycin, and then mixed with test antibody and
cultured for 40 h at 1% hematocrit. Test samples were prepared
by taking protein G eluate (see “IgG purification”) or protein
samples (see “Protein expression and purification”), and buffer
exchanging three times into incomplete culture medium (lacking
serum and gentamycin) using Amicon 10K MWCO centrifugal
filtration devices. To deplete RBC-reactive antibodies, some
samples were then incubated for 1 h with 100 µL O+ RBC at
100% hematocrit per mL of serum before centrifugation and
removal of supernatant. Dialysis to exclude possibility of azide
contamination was performed with Pierce MINI dialysis devices
into incomplete culture medium.
Detection of parasite and inference of growth was performed
using the lactate dehydrogenase method. BG98 is a rabbit anti-
AMA1 purified immunoglobulin antibody pool (provided by
Edmond Remarque, BPRC, Netherlands). It typically gives 80–
90% GIA at 6 mg/mL and was used for quality control on
assay runs.
Prediction of the GIA of an antibody mixture, GIAA+B, given
knowledge of the GIA of individual components (GIAA and
GIAB), assuming Bliss Additivity between components, followed
the equation (30):
GIAA+B = [1−
(
1−
GIAA
100
)
×
(
1−
GIAB
100
)
]× 100
Schizont Extract Western Blot
For Figure S3E, schizont and RBC extract were prepared
by taking synchronized cultures of 3D7 clone schizonts or
uninfected RBC, then pelleting and resuspending in a 10x
volume of Laemmli buffer containing 2-mercaptoethanol, then
subjecting to three cycles of freezing and thawing. Extracts were
separated on 4–20% polyacrylamide gels along with Prestained
Protein Marker, Broad Range (New England Biolabs, USA)
and then blotted onto nitrocellulose membrane. Membranes
were probed with total IgG from immunized mice at 20µg/mL
as primary antibody, then detected with alkaline phosphatase-
conjugated anti-mouse IgG secondary antibody (Jackson, USA),
using p-nitrophenylphosphate (pNPP) (Sigma Aldrich, USA)
dissolved in water for detection.
Antigen-Specific Antibody Affinity
Purification
CyRPA-specific rabbit IgG samples were generated in two
stages. Total IgG was purified as above using protein G-
sepharose. CyRPA-specific IgG was then purified from the
total IgG using CyRPA-conjugated sepharose columns. These
were generated using CyRPA (GlyKO)-C-tag protein and NHS-
activated Sepharose 4 Fast Flow (GEHealthcare) according to the
manufacturer’s instructions. Total IgG was diluted 1:10 in 50mM
Na2HPO4 and applied to CyRPA-treated sepharose columns
five times. After washing with 10 column volumes of 50mM
Na2HPO4 to remove the non-specific antibody, CyRPA-specific
IgG was eluted with 0.1M glycine and restored to neutral pH
by addition of Trizma pH 9.0, before three rounds of buffer
exchange into PBS using an Amicon 10K MWCO centrifugal
filtration device.
ELISA
96-well Maxisorp plates were coated overnight with 100 ng/well
CyRPA (GlyKO)-C-tag protein (glycan sites ablated) in PBS and
then blocked with 10%milk powder. Test samples and secondary
antibody (anti-mouse IgG (whole molecule) produced in goat
and conjugated to alkaline phosphatase, Sigma, UK) were diluted
in PBS plus 0.05% Tween-20. Alkaline phosphatase activity
was measured by breakdown of pNPP using optical density at
405 nm (OD405). Anti-OVA and anti-AARP titer was measured
by defining the dilution factor required for a sample to yield a
negative OD405, defined as 0.15 using a pre-immune negative
reference. For CyRPA, a standardized ELISA was also established
according to principles outlined in (31) and automated by Gen5
software (BioTek, USA). Briefly, serum from the six rabbits
shown in Figures 5, 6 was pooled to make a standard sample
whose concentration of anti-CyRPA IgG antibody was defined
as 8,000 arbitrary units (AU). This sample was used to construct
standard curves on assay plates. Samples were diluted such that
they gave an OD405 lying on the linear region of the standard
curve (generally between OD405 0.3 and 2). The AU of the
starting sample was then back-calculated based on the dilution
of the sample and its position on the standard curve.
Anti-CyRPA Antibody Quantification by
Concentration-Free Calibration
Analysis (CFCA)
Our approach to CFCA has been described previously (30). To
generate a source of mono-biotinylated CyRPA for use on a
streptavidin Biacore capture chip, HEK293 cell cultures were co-
transfected with a plasmid encoding CyRPA (GlyKO) (Figure S6)
and a second plasmid encoding the BirA biotin ligase, and after
4 days centrifuged and filtered to remove cell debris prior to
extensive dialysis into PBS. Total IgG samples were assayed at a
1:1,000 dilution of the concentrations shown in Figure 6C.
Statistics
Analysis was performed using GraphPad Prism version 5.04
(GraphPad Software Inc., USA). Tests and statistics are
described in Figure Legends. To determine EC50 values from
Figures 5E,F, for each individual rabbit a four-parameter
sigmoidal dose-response curve was fitted to the relationship
between log10(antibody concentration) and GIA, and then used
to interpolate EC50s for each rabbit. To generate conversion
factors for ELISA AU into µg/mL of affinity purified CyRPA-
specific IgG for each individual rabbit, linear interpolation was
performed between individual data points for immune rabbits
and the pre-immune data point in Figure 6A.
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RESULTS
Protein-In-AddaVaxTM Immunization
Induces High-Titer Antibodies in
BALB/c Mice
Freund’s adjuvant has been widely used in the generation of
high-titer polyclonal antibodies against proteins of interest.
However, its suitability for the testing of potential vaccine
antigens in animal models is questionable. Evidence that it can
disrupt the tertiary structure of proteins (16), along with ethical
issues concerning the adverse reactions associated with its use,
persuaded us to consider alternatives for an antigen screening
programme in mice. A previous study in our laboratory reported
AbISCO R©-100 as a potent, alternative preclinical adjuvant (28)
and a more refined replacement for the Freund’s adjuvant system.
However, the promising and on-going clinical development of
Matrix-M (32) (the successor formulation of AbISCO R©-100),
made acquiring this adjuvant difficult at the time of performing
the study and so we examined instead AddaVaxTM, a preclinical
analog of the licensed human adjuvant MF-59 which is a
squalene-based oil-in-water emulsion (33, 34). Mice immunized
with chicken egg ovalbumin (OVA) formulated with AbISCO R©-
100 and AddaVaxTM produced comparable titers of anti-OVA
serum IgG antibodies (Figure S1) and so we proceeded with
AddaVaxTM adjuvant for subsequent experiments.
Production of a Panel of
Protein-In-Adjuvant Pre-clinical Vaccines
Fifty-five proteins of interest were selected, falling into
two categories:
The first category consisted of 15 proteins, described in the
literature as having properties that are desirable in a merozoite-
blocking vaccine. These proteins met at least one of the following
criteria: (i) susceptibility to vaccine-induced antibody, in vitro or
in vivo; (ii) established involvement in the process of merozoite
egress from schizonts or invasion into new RBC; (iii) essential to
parasite viability, generally defined by reported failures to disrupt
the relevant gene; or (iv) strong association with protection
from clinical malaria in sero-epidemiological studies (Table S1).
Candidate antigens which have already been characterized in
our laboratory such as merozoite surface protein 1 (MSP1),
erythrocyte-binding antigen-175 (EBA175), RH2, and RH4 were
excluded [see (7) for full list]. We have previously attempted
to produce viral vectors expressing MSP2 which were not
immunogenic and which were subsequently found not to express
MSP2 in mammalian cells (unpublished data). We therefore also
excluded this protein from the literature-selected list.
The second category contained forty proteins selected from
a pool of 435 genes whose protein products are implicated
bioinformatically inmerozoite invasion of RBC (18). A schematic
for the selection of these 40 proteins is shown in Figure S2. Of
these 435 genes, 104 are predicted to encode a signal peptide
(35). A signal peptide is likely to be an essential property for
traffic to the parasite surface, potentially via invasion-associated
organelles, and is also true of all validated targets of merozoite-
neutralizing antibody including MSP1, apical membrane antigen
1 (AMA1), RH5, RH4, and EBA175. Eliminating 18 proteins
longer than 1,333 amino acids (due to challenges in synthesizing
genes more than 4,000 bp in length), and 16 proteins which have
previously been tested in our laboratory as vaccine antigens left a
total of 70.
To select the final 40 from this list of 70 we ranked proteins
according to polymorphism, with the intention of selecting
the least polymorphic (see Methods)—it should be noted that
subsequent and ongoing consolidation of genomic data into
the MalariaGen portal (www.malariagen.net) means that the
numbers of SNPs, and especially the frequencies within the
population, have changed since our accessing these data in mid-
2012. However, using AMA1, RH5, and RH4 as benchmark
proteins we found that polymorphism across the list of 70 was
much lower than expected. AMA1, a protein affected by strain-
specific neutralization, has 34 SNPs, making it substantially more
polymorphic than any protein in the set of 70. However, even
proteins likely unaffected by strain-specific neutralization such as
RH5 (4 non-synonymous SNPs) and RH4 (3 non-synonymous
SNPs) also ranked among the top third most polymorphic
proteins in the set. In fact, 33 of 70 proteins were found
to contain zero non-synonymous SNPs of >10% prevalence.
Presumably, RH4, and RH5 are still under a minimal degree of
immune pressure which is absent for the proteins with no SNPs.
This result meant that our original plan to select the 40 least
polymorphic proteins from the list of 70 would have resulted in
the exclusion of RH5 and RH4, which was counter to our overall
strategy of selecting proteins with a similar profile to RH5.
We therefore changed our strategy for triage by
polymorphism, aiming to select proteins with evidence of
immune pressure, but without so many polymorphisms as to risk
strain-specific immunity, i.e., a panel of minimally polymorphic
proteins. Excluding 30 of the proteins with no SNPs of >10%
prevalence left 40 proteins that, on the level of SNPs, resembled
RH5 far more than they resembled AMA1 (see Table S2). The
final selection contained 27 proteins with 0–5 SNPs, 8 proteins
with 6–15 SNPs, and 5 with 15–25 SNPs. Of the literature-
selected panel of 15 proteins, 8 would also have been identified
using the final bioinformatic selection algorithm (Table S1).
We also aimed to minimize the probability of producing
small polypeptide fragments that do not fold correctly and
hence fail to elicit a functional antibody response, as occurred
with RH5 in early studies of this target (7, 13, 14). Therefore,
where possible, we aimed to express the entire ectodomain of
the 55 shortlisted proteins. An important decision when using
mammalian expression systems is whether to retain or ablate
predicted sites of N-linked glycosylation (defined as N-X-S/T,
where X is any animo acid residue except proline). As various
Plasmodium antigens have been shown to elicit functional anti-
parasitic antibody responses without modification to the primary
amino acid sequence after expression in situ from mammalian
cells (36–38), we obtained constructs that encoded the amino
acid sequence exactly as predicted from the 3D7 clone parasite
reference genome for all but one antigen candidate [P113 being
the exception, the synthetic gene was the same as that used
in a previous study and already had N-linked glycan sequons
ablated (39)]. For SEA-1 and CyRPA, for which particularly
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promising vaccine antigen characteristics have been reported
in the literature (40, 41), in addition to the native amino acid
sequence, we also obtained constructs encoding versions of
the protein with N-linked glycan sequons ablated (comparison
shown in Table S1), in order to minimize the probability of a
false-negative result in screening.
Mammalian expression plasmids encoding the 55 proteins of
interest were successfully cloned and subsequently transfected
into 500mL cultures of HEK293E cells. Of the 55 different P.
falciparum proteins, sufficient protein for a small scale mouse
immunization campaign (approx. 300 µg, requiring expression
at >0.6µg/mL of cell culture supernatant) was obtained for 20
(Figure 1). This equates to a success rate 36.4% and is roughly
in line with a previous attempt to produce a protein library
using suspension HEK293 cells (42). We had significantly more
success with the literature-selected panel than the bioinformatic
panel (9/15 vs. 11/40, Fisher’s exact test P = 0.0329), presumably
reflecting publication bias toward proteins that can be expressed
recombinantly. In a logistical regression analysis, neither protein
length (OR = 0.9965, 95% CL 0.9914–1.0015) nor number of
SNPs (OR = 0.8705, 95% CL 0.7125-1.0636) were predictive of
expression in a statistically significant manner. Most proteins
ran at a higher molecular weight than that predicted by the
primary structure. Both variants of SEA-1 and CyRPA could also
be expressed (Figures 1A,B). For SEA-1, no obvious difference
in banding pattern was observed between the native version and
the glycan-ablated version, and both constructs contained an
additional band at approximately 75 kDa, which may represent
the presence of a contaminant of SEA-1 dimer (Figure 1A). SEA-
1 contains only two N-glycan sequons, both of which are judged
unlikely to be glycosylated by the NetNGly server (http://www.
cbs.dtu.dk/services/NetNGlyc/). The glycan-ablated version of
CyRPA ran as a sharper band than the native version, presumably
due to the presence of multiple glycoforms in the native version
as CyRPA (native) contains 3 potential N-glycosylation sequons
(Figure 1B and Figure S6). For many proteins, multiple smaller
bands were observed, probably arising from proteolytic cleavage
of the full-length construct. Given that the full-length protein
was likely to be present, the presence of these smaller bands was
deemed acceptable for screening purposes. Purified proteins were
subsequently formulated with AddaVaxTM adjuvant to produce
pre-clinical protein-in-adjuvant vaccines.
Vaccines Induced Antigen-Specific IgG
With Variable Neutralizing Activity
Groups of 4 mice were immunized with the vaccines over
several independent experiments. Each experiment contained
mice immunized with RH5 (7) as a functional antibody positive
control and mice immunized with OVA as a negative control.
Because production of RH5 protein at the time of vaccine
preparation was not yet optimized, yield was low and therefore
only the first experimental group received RH5 protein-in-
adjuvant vaccine (Figure 1A) while subsequent groups received
RH5 viral vectors. Gels in Figure 1 show proteins immediately
prior to formulation with AddaVaxTM adjuvant. Following
completion of the immunization phase, serum was harvested
by terminal cardiac bleed. IgG was purified from the pooled
sera of each group of mice and tested for binding to late
schizonts by immunofluorescence (Figure 2). Total IgG from
mice immunized with RH5 reacted strongly to schizonts whereas
IgG from OVA-immunized mice did not. Of the remaining
protein constructs tested, all but AARP-BAP-Strep and MSP11-
BAP-Strep elicited IgG that reacted with schizonts. Although
this experiment was not designed to assess localization, we
did compare our results with previous studies to confirm
similar staining patterns (Table S3). Most antibody samples
showed staining consistent with previous reports, but for three
proteins it was unclear whether our findings were in agreement
with published work. Anti-ASP antibodies showed a punctate
pattern as expected (43, 44), but additionally stained the
external perimeter of the schizont. Pf92 was found to stain
in a punctate manner, in contrast to a previous study using
GFP-tagged Pf92 that localized to the merozoite surface (45).
The GFP construct used in this study may have had non-
natural trafficking, explaining the difference seen with our
antibodies against native 3D7 parasite. Finally, a previous report
has identified P113 as an interaction partner with RH5, and
localized it to the surface of merozoites (39); however we were
unable to identify any schizonts exhibiting merozoite surface
staining with P113 (Figure 2), with staining more characteristic
of the parasitophorous vacuole or iRBC surface, consistent with
previous proteomics work (46).
Purified serum IgG was next screened for neutralizing activity
in the in vitro assay of GIA at 1 mg/mL (Figures 3A–D).
Anti-RH5 antibodies, whether raised using protein-in-adjuvant
or virus vectors, had GIA ranging from 48 to 67%, whereas
antibodies raised against OVA had < 5% GIA. In this initial
screening, three vaccines appeared to have elicited functional
antibodies which merited further study: CyRPA (Figure 3A), S-
antigen and AARP (Figure 3B). All other IgG samples showed
< 10% GIA at 1 mg/mL, which is indistinguishable from
background GIA with anti-OVA antibodies.
Investigation of Antibodies Against AARP
and S-Antigen
Given the screening results above, we next sought to further
analyse the antibodies against S-antigen and AARP. Murine
polyclonal IgG antibodies to AARP showed high-level GIA
against both 3D7 and FVO parasites (Figure 4A). However, given
that the murine anti-AARP antibodies showed no discernible
binding to schizonts in the IFA assay (Figure 2), their ability
to neutralize parasites in the assay of GIA raised concerns
about their mechanism of action and the validity of this
result. We first aimed to rule out contamination of the sample
with sodium azide, which is present in small amounts in the
protein G binding buffer used for IgG purification. Dialysis
of the small amount of remaining antibody sample showed
that small molecule contamination was unlikely (Figure S3A).
These experiments depleted the remaining sample of IgG from
the screening experiment, however a subsequent attempt to
immunize rabbits with AARP-BAP-Strep did not yield functional
antibodies (Figure S3B). Therefore, a further 10 mice were
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FIGURE 1 | Twenty-two protein antigens representing 20 different P. falciparum proteins. Just prior to formulation with AddaVaxTM and immunization into mice,
approximately 2 µg protein was analyzed by reducing SDS-PAGE. Four immunization campaigns were run in total, with (A,B) combined into one campaign, and
(C–E) each having their own campaign. (A) also includes analysis of “GIA positive” and “negative” control proteins, RH5, and OVA.
immunized again exactly as for the screening study with AARP-
BAP-Strep protein, and serum from pairs of mice was pooled
to give five samples. Interestingly, three of the five samples
showed high GIA whereas the remaining two samples showed
no GIA (Figure S3C). To test whether the functional antibodies
in the samples cross-reacted with the RBC surface, we pooled
the five samples and assessed GIA after an RBC pre-incubation
step (Figure 4B). RBC pre-treatment totally ablated all GIA of
the anti-AARP antibodies in a manner comparable to the anti-
basigin mAb TRA-1-85 (10) (a mAb against the RH5 receptor,
used here as an anti-RBC control). Notably, these results with
anti-AARP IgG contrasted with anti-AMA1 antibodies where
no effect of RBC pre-incubation was seen (Figure 4B). These
data suggested that the mechanism of GIA of IgG from mice
immunized with AARP was through binding to a molecule on
the RBC surface. Alternatively, the inhibitory antibodies raised
by vaccination with this protein preparation may function by
neutralizing the parasite, but also cross-react to a non-inhibitory
epitope on RBCs. The negative anti-schizont IFA (Figure 2)
points away from this latter conclusion.
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FIGURE 2 | Eighteen of twenty antigens elicit antibodies that react with P. falciparum schizonts. Groups of 4 mice were immunized with the proteins in adjuvants as
shown in Figure 1. Seven days after the final injection, serum was harvested and pooled for each group before purification of IgG using protein G. The IgG was then
probed for reactivity to paraformaldehyde-fixed schizonts in an immunofluorescence assay at a total IgG concentration of 20µg/mL. All images were captured using
the same microscope settings on the same day. Scale bar = 5 µm.
To further interrogate this, we prepared a new batch of AARP-
BAP-Strep protein and tested its ability to reverse the GIA of
the murine anti-AARP IgG antibodies. GIA from the anti-AARP
antibodies could not be reversed by the addition of 2.5 mg/mL of
the new batch of AARP-BAP-Strep protein, whereas 2.5 mg/mL
AMA1-BAP-His protein was sufficient to fully deplete the GIA
activity of anti-AMA1 IgG antibodies in the assay (Figure 4C).
Taken together these results did not support neutralization of
parasite AARP by IgG raised in our screen as a mechanism of
GIA; they also suggested that antibodies against a HEK293 cell
contaminant protein in the AARP vaccine were the most likely
cause of the GIA. We could also not ascertain as to why this
only occurred with the AARP protein vaccine in mice (noting
we failed to induce growth inhibitory IgG in rabbits immunized
with the same protein), and therefore we could not exclude the
possibility of murine antibodies binding to a cryptic epitope
such as a transient conformer of AARP or a rare glycoform,
which cross-reacted with human RBC. Of note, AARP does carry
two glycosylation sequons and AARP-BAP-Strep as expressed
did contain PNGase-sensitive glycans (Figure S3G). Attempts to
express AARP using a construct with glycan sequons ablated were
not successful in the HEK293 system (data not shown).
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FIGURE 3 | Growth inhibitory activity of antibody specificities. The protein-G purified total IgG samples tested for schizont reactivity as shown in Figure 2 were
screened for activity in the standardized assay of GIA at 1 mg/mL. Each of panels (A–D) represents IgG from one independent mouse immunization campaign.
Samples were not subjected to pre-incubation with RBC prior to GIA testing. Data is shown as mean of triplicate wells of a single GIA assay, and are representative of
two independent assays.
Given the high level of neutralization of the antibodies, and
their ability to strongly inhibit the growth of two divergent
P. falciparum strains (Figure 4A) we attempted to further
characterize the mechanism of neutralization by comparing the
properties of the three pools shown in Figure S3C that did have
GIA with the 2 pools that did not. However, we were hampered
by the relatively small sample volume that can be obtained
from mouse serum and an inability to produce functional rabbit
antibodies (Figure S3B). The five samples shown in Figure S3C
showed no difference in anti-immunogen ELISA (Figure S3D),
and no consistent difference in binding to either schizont lysate
or RBC lysate as measured by Western blot (Figure S3E).
Notably, previous reports of AARP as a candidate vaccine
antigen have expressed a short construct of AARP from E. coli
[amino acids I20-D107 (9, 47)]. We therefore tested a construct
mirroring this published version as closely as possible. We were
only able to produce a construct encoding residues I20-D95 in E.
coli (Figure S3F). We found that when formulated in AddaVaxTM
and immunized into mice, antibodies elicited by this construct
did not have any GIA, in contrast to AMA1 (Figure S3H).
In light of these data, we elected to not pursue this candidate
antigen any further and processed to assess antibodies against
the second hit in our screen—S-antigen. Here results were
more promising. Murine polyclonal IgG antibodies to S-antigen
showed GIA against both 3D7 clone and FVO strain parasites
(Figure 4D), an effect that was reproduced against the 3D7
clone using immunized rabbit polyclonal IgG antibodies pre-
depleted with RBC (Figure 4E). Importantly, mixing of purified
S-antigen protein with rabbit total IgG could reverse the GIA of
S-antigen antibodies, but not RH5 antibodies (Figure 4F). The
antibodies isolated from mice immunized with S-antigen were
probed against schizont extract by Western blot (Figure S5) and
found to react to a single band of similar size to the recombinant
S-antigen in Figure 1. These results suggest that S-antigen can be
a target of neutralizing vaccine-induced antibodies. The ability
of antibodies to neutralize 3D7 and FVO parasite was surprising
because S-antigen is polymorphic (Figure S4), with 3D7 and
FVO varying substantially: even among the relatively conserved
97-amino acid N-terminus of S-antigen, there are 41 sites of
amino-acid divergence, with FVO and 3D7 diverging at 27 of
these (Figure S4).
Investigation of Antibodies Against CyRPA
In our initial antigen screen, we found a striking difference
in the potency of the polyclonal IgG mouse antibodies elicited
to CyRPA (Gly KO) compared to CyRPA (native), both
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FIGURE 4 | Functional activity of anti-S-antigen and anti-AARP antibodies in the assay of GIA. (A) Titration of the same anti-AARP-BAP-Strep sample shown in
Figure 3B against the 3D7 clone and FVO strain. (B) Effect of RBC pre-incubation on a range of mouse antibody specificities. TRA-1-85 is a mouse anti-basigin
monoclonal antibody. Other samples are total IgG from immunized mice (see Figure S3 for further details). (C) Pre-mixing of the relevant immunizing antigen with
mouse total IgG. Final antigen concentration was 1.35 mg/mL, IgG concentration was 1 mg/mL. (D) Titration of the same anti-S-antigen-BAP-Strep sample shown in
Figure 3B against the 3D7 clone and FVO strain. (E) Total IgG from two Zika rabbits immunized with S-antigen-BAP-Strep formulated with Freund’s adjuvant system.
Samples were subjected to pre-depletion with RBCs. (A–D) are each from a single GIA assay run due to sample volume constraints. (A,D), lines are connected mean
and points individual replicate wells (two per concentration). (F) Pre-mixing of S-antigen protein with pooled rabbit total IgG from (E). Final S-antigen concentration
was 1.5 mg/mL, total IgG concentration was 10 mg/mL. (A–D), mean and range of four replicates. (E,F), mean and range of three wells of a single GIA assay,
representative of data from two replicate GIA assay runs.
quantitatively in terms of their potency (Figure 3A) and their
ability to combine with rabbit anti-RH5 IgG antibodies (7) to
give a synergistic level of GIA (Figures 5A,B). Consistent with
a previous report on these two antigens (41), the combination
of anti-CyRPA (Gly KO) and anti-RH5 IgG here showed
synergy in the assay of GIA across two replicate assays. Aside
from the amino acid substitutions to remove potential sites
of N-linked glycosylation (S147A, T324A, T340A, schematic
in Figure S6), these constructs differed markedly. The CyRPA
(GlyKO) expression plasmid was a kind gift from Gavin Wright
and colleagues, who use murine Ig signal peptide, and notably
include a 20.4 kDa epitope tag on CyRPA (Gly KO) derived
from rat CD4 domains 3 and 4 (CD4d3+4) (Figure S6) (48).
However, before investigating which, if any, of these differences
in construct design had led to differing qualities of anti-CyRPA
IgG, we sought to reproduce the synergy result with the CyRPA
(Gly KO) vaccine and immunized new cohorts of mice and
rabbits with a new batch of CyRPA (Gly KO) protein. The IgG
antibodies elicited by the CyRPA (Gly KO) antigen formulated
with AddaVaxTM reproducibly showed GIA against 3D7 clones
parasites in both mice (Figure 5C) and rabbits (Figure 5E). We
also tested formulation with Poly(I:C), a fully aqueous molecular
adjuvant system, and saw diminished GIA activity by comparison
to AddaVaxTM adjuvant in mice (Figure 5D). The rabbit anti-
CyRPA antibodies also showed high-level neutralization of the
FVO strain (Figure 5F). However, the synergy observed in our
initial experiment (Figure 5A) was not observed in subsequent
experiments using IgG purified from newly immunized mice
(Figures 5C,D) or rabbits (Figure 5G); only an additive effect
was observed.
Given these conflicting data, we sought to confirm the validity
of the initial result showing synergy between antibodies against
CyRPA (Gly KO) and RH5. It was observed in the initial
experiment (Figure 5A) that the anti-CyRPA (Gly KO) purified
IgG antibodies caused agglutination of the RBC in the GIA
assay, and we sought to exclude this as a mechanism of GIA.
We found that pre-depletion of the mouse IgG antibody sample
with human RBC ablated the agglutination observed and had
no effect on the GIA, either as a single specificity or its ability
to synergize with anti-RH5 IgG (Figure S7A). To exclude any
Frontiers in Immunology | www.frontiersin.org 10 June 2019 | Volume 10 | Article 1254
Illingworth et al. Comparison of Blood Stage Malaria Antigens
FIGURE 5 | Functional activity of anti-CyRPA antibodies in the in vitro assay of GIA. (A,B) Titration of the anti-CyRPA purified IgG samples (from Figure 3A) against
3D7 clone parasites, with (blue line) and without (black line) addition of a fixed concentration (1.25 mg/mL) rabbit anti-RH5 purified IgG antibodies. Dashed line shows
the activity of the anti-RH5 IgG alone tested at the single fixed concentration and red line shows the calculated activity of the mixture, assuming Bliss additivity (30).
Dotted line indicates 50% GIA. (C) A new sample of mouse anti-CyRPA (GlyKO) IgG was generated and assessed as in (A). (D) A new sample of mouse anti-CyRPA
(Gly KO) IgG was generated using an identical immunogen to (A,C), but using Poly(I:C) adjuvant for formulation. (E,F) Six rabbits were immunized with CyRPA (Gly
KO) in AddaVaxTM and their total IgG tested in a titration series for GIA against 3D7 clone and FVO strain parasites. (G) Pooled IgG antibodies from the six rabbits in
panels (E,F) were tested for synergy against the 3D7 clone with anti-RH5 IgG antibodies as in (A,B). (H) GIA of total IgG purified from 20 individual mice immunized
with CyRPA (Gly KO) and AddaVaxTM, each tested at a different concentration as defined by IgG yield in the sample. All panels show representative results from two
replicate GIA assays, except (E) which was repeated 3 times. Each point shows the mean of three replicate wells; error bars show the range of three replicates wells.
effect of possible anti-rat CD4d3+4 antibodies we also generated
recombinant CyRPA with a C-terminal four amino acid C-tag
(25), which contained the same CyRPA (Gly KO) sequence but
lacked the CD4d3+4 domain, called CyRPA (Gly KO)-C-tag
(see Figure S6 for construct comparisons). A vaccine containing
CyRPA (GlyKO)-C-tag yielded functional antibodies comparable
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FIGURE 6 | Potency of vaccine-induced anti-CyRPA antibodies from six individual rabbits. See Figure S8 for experimental schematic. A second batch of IgG was
purified from the six rabbits shown in Figures 5E,F, as well as one pool of pre-immune IgG, using protein G. (A,B) Calculation of antigen-specific IgG concentration by
affinity purification (AP) and ELISA analysis. (A) Total IgG from six individual rabbits was passed over a CyRPA-sepharose column and the six eluates were analyzed for
total protein concentration by OD280, and assayed for CyRPA binding by ELISA, to generate a conversion factor for each rabbit. Points are individual rabbits, solid line
is mean conversion factor (shown for information only—not used in calculations), dashed lines 95% CI (actual calculations were performed with separate conversion
factors for each individual rabbit). (B) GIA data from Figure 5E transformed using the conversion factors determined for individual rabbits in panel A, to show CyRPA
antigen-specific IgG concentration. Points are means of 3 assay well replicates, error bars show range of three replicates. (C) Calibration-free concentration analysis
(CFCA). Total IgG was analyzed for total protein concentration by OD280, and anti-CyRPA antigen-specfic IgG concentration by CFCA. Pre-immune IgG gave a
sub-detectable CFCA response. (D) Interpolated GIA EC50s for the six CyRPA immunized rabbits. Points are individual rabbits, bars are means.
to the parental CyRPA (Gly KO) construct as a single specificity,
however, these also showed additivity, but not synergy, with anti-
RH5 IgG antibodies (Figure S7B), meaning that a role for anti-
CD4 IgG cannot be excluded in the results from Figure 5A.
Consequently, in a final effort to understand the mechanism
of the synergy seen in Figure 5A, we immunized with CyRPA
(Gly KO) and harvested IgG from individual mice, aiming to
isolate monoclonal antibodies (mAbs) from mice whose serum
polyclonal IgG showed synergy with anti-RH5 antibodies. IgG
yields from individual mice were variable, necessitating GIA
screening at a range of concentrations (Figure 5H). Although
IgG from most mice showed GIA, not one of the IgG samples
isolated from these 20 mice showed synergy with anti-RH5
antibodies and isolation of mAbs was not pursued (data not
shown). Therefore, given the inconsistency of synergy observed
in our study, we attempted to replicate as closely as possible
the initial report of anti-CyRPA and anti-RH5 IgG antibody
synergy, which used rat immunization with Freund’s adjuvant
(41). A pair of Wistar rats and a pair of Sprague Dawley rats
were immunized with CyRPA (Gly KO) in Freund’s adjuvant.
Total IgG isolated from these rats showed 60–90% GIA at the
highest concentrations tested, and some degree of additivity with
anti-RH5 rabbit IgG, but no synergy was seen (Figures S7C–F).
Thus, these data suggest that anti-CyRPA IgG raised in mice,
rats and rabbits can elicit substantial GIA and that this is most
consistently additive when combined with anti-RH5 rabbit IgG.
Assessment of Anti-CyRPA Specific
IgG Potency
Given immunization against CyRPA could reliably elicit
functional antibodies, we next aimed to better assess CyRPA’s
suitability as a candidate vaccine antigen by quantifying its
susceptibility to vaccine-induced polyclonal antibody. We and
others have previously reported similar analyses for polyclonal
antigen-specific IgG against RH5, AMA1, and MSP1 in different
species ranging from mice through humans (1, 4, 30). Here, for
rabbit anti-CyRPA antibody, the mean total IgG concentration
giving 50% GIA (EC50) against the 3D7 clone parasite was
5.07 mg/mL (95% CI, 3.61–6.54, Figure 5E) and against the
FVO strain was 5.34 mg/mL (95% CI, 3.83–6.86, Figure 5F).
However, the antigen-specific IgG is typically only a small
fraction of the total IgG; so we next determined the proportion
of total IgG which is CyRPA-specific using two methods:
(i) affinity purification of specific IgG using chromatography
columns loaded with CyRPA antigen; and (ii) surface plasmon
resonance analysis by calibration-free concentration analysis
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(CFCA) using recombinant CyRPA coated onto a capture chip.
The experimental schema is shown in Figure S8.
When using the affinity-purification method, CyRPA-specific
IgGwas purified from total rabbit IgG using CyRPA-immobilized
sepharose columns. The total protein concentration (assumed
to be all antigen-specific IgG) was then analyzed by OD280
measurement as well as measured for anti-CyRPA responses
in arbitrary units (AU) by ELISA (Figure 6A). This was
used to calculate a conversion factor for ELISA AU to a
specific concentration of anti-CyRPA rabbit IgG antibodies in
mg/mL for each individual rabbit (for information only, mean
conversion factor: CyRPA-specifc IgG concentration (µg/mL)
= 0.046 (ELISA AU)−0.1; slope 95% CI 0.058–0.043). We
then measured the ELISA units of the IgG stocks used to
perform the GIA in Figure 5E and replotted GIA against CyRPA-
specific IgG (Figure 6B).
For CFCA, total IgG from individual rabbits was analyzed to
assess the concentration of anti-CyRPA antibodies in samples
whose total protein concentration was measured by OD280
(Figure 6C). For the pre-immune rabbit IgG pool, the anti-
CyRPA CFCA response was sub-detectable. For the six immune
IgG samples, the mean proportion of CyRPA-specific IgG as
measured by CFCA was 6.78% of the total IgG (95% CI, 2.86–
10.7%). With the proportion of total IgG that was specific for
CyRPA now determined for each rabbit, GIA was replotted
against CyRPA-specific IgG (not shown), and the antigen-specific
GIA EC50 values calculated with each method were compared
(Figure 6D). The CyRPA-specific rabbit IgG GIA EC50 was
calculated to be 470µg/mL by the affinity purification method
(95% CI: 270–680µg/mL) and 330µg/mL for the CFCA method
(95% CI: 190–480µg/mL), with the figure determined by affinity
purification significantly higher than by CFCA (P = 0.031,
Wilcoxon matched-pairs signed rank test). Both figures suggest
that relatively high Ag-specific antibody concentrations are
required for CyRPA polyclonal IgG mediated GIA.
DISCUSSION
RH5 has emerged as a leading blood-stage vaccine candidate
antigen, and vaccination with this antigen appears to elicit a
potent growth-inhibitory antigen-specific antibody response (1,
12). A recombinant protein vaccine called RH5.1 based on this
antigen is currently in Phase I/II clinical trials (11). The objective
of this study was to shed light on whether there are other
antigens that could supersede or synergize with RH5 in their
ability to elicit growth-inhibitory antibodies against blood-stage
P. falciparum. This will inform the approach taken to improve on
the present RH5 vaccine and/or develop next-generation vaccine
formulations targeting multiple antigens to achieve even higher
levels of growth inhibitory antibodies.
To meet this objective, we tested a range of merozoite proteins
in as unbiased a manner as possible, testing their ability to
elicit antibodies with functional GIA. RH5 was used as a “gold-
standard” antigen. Fifty-five proteins of interest were selected for
study: 15 were selected from the literature as having properties
desirable in a vaccine antigen; while the other 40 proteins were
selected on the basis of a bioinformatically predicted role in
merozoite invasion (18). These 40 proteins were selected from
a shortlist of 70 on the basis of having a higher number of
SNPs. Of the 55 proteins selected, 20 were successfully expressed,
and for 18 we were able to raise an antibody response that
showed binding to fixed schizonts. While an expression success
rate of 20/55 proteins is high compared to an expression library
effort using a bacterial system (49), and in line with a recent
study using suspension HEK293 cells (42), this leaves 35 proteins
unaddressed by this study. Alternative expression systems using
insect cells (29) and protozoan cells (50) may achieve a higher
success rate in future studies.
When tested for function in the in vitro assay of GIA, three
antibody specificities showed functional activity when tested
alone: S-antigen; AARP and CyRPA. While our finding that
S-antigen can be a target of neutralizing antibody is novel,
AARP and CyRPA have been the subject of previous publications
highlighting promise for these proteins as clinical candidate
vaccine antigens. We therefore scrutinized the latter two antigens
particularly closely, to help inform the immediate prioritization
of antigens for inclusion in the next generation of clinical
vaccine candidates. For S-antigen, purified IgG samples from
immunized mice and rabbits (that had also been pre-depleted
with RBC) were able to inhibit growth in a reproducible
manner, and this effect could be reversed by pre-incubation
with S-antigen protein. S-antigen has been largely unstudied
since the 1980s, and was included in this screen because of
statements in review articles authored by Cowman et al. that S-
antigen is refractory to genetic ablation (51, 52). Interestingly,
while most of the 14 other proteins that were initially selected
based on literature reports as showing a role in merozoite
invasion would also have been identified using the bioinformatics
approach used to identify the other 40 proteins (18), S-antigen
was not identified bioinformatically as having a role in this
process. It is therefore surprising that S-antigen appears to be
the target of neutralizing antibody in the GIA assay. Given
the extreme variability of S-antigen between strains [Figure S4,
and also (53)], the ability of antibodies raised to the 3D7
clone sequence of S-antigen to neutralize the FVO strain was
particularly unexpected. Although we did not follow-up this
result further, our data suggest S-antigen may warrant re-
visiting in future vaccine studies, with particular emphasis on
defining the neutralizing epitopes and understanding the effect
of polymorphism between strains.
Different antibody samples raised against AARP did not show
consistent functional GIA, and further investigation suggested
the function was likely mediated through off-target binding of
antibodies to the RBC. Notably, previous publications ascribing
a high level of neutralization activity to anti-AARP antibodies
do not describe an RBC pre-incubation step in the purification
and preparation of IgG from serum (9, 47), and we were unable
to reproduce these results with a similar, albeit not identical,
immunogen. Our negative results for AARP in rabbits are
consistent with those described in a separate, recent antigen
screen (54). Although we elected to not study this antigen
any further, future identification of the RBC moiety bound by
the neutralizing anti-AARP IgG samples could potentially yield
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important information about the mechanism of invasion of RBC
by merozoites.
In the case of our final “hit,” immunization with CyRPA-
based constructs could reproducibly elicit antibodies from mice,
rats and rabbits with invasion-blocking activity. The first mouse
IgG sample we produced exhibited synergy when combined
with anti-RH5 rabbit IgG antibodies across numerous replicate
assays, in line with an earlier report on this antigen combination
(41). However, the fact that multiple subsequent immunizations
did not yield GIA with this synergistic property, including rats
immunized using an almost identical protocol to that used by
Reddy et al. (41), suggests that it is highly likely a result of
rare antibody clones binding to specific epitopes. It could be
that use of AddaVaxTM adjuvant biased the antibody response
toward a non-synergistic repertoire of epitopes, although a
similar result was obtained when using Freund’s adjuvant in rats.
Although synergy between RH5 and CyRPA IgG specificities
was inconsistent, the combination did consistently result in
additive GIA in our hands, in agreement with some other reports.
Bustamante et al. found that the combination of RH5 and
CyRPA total IgG from immunized rabbits alternated between
synergy and sub-additivity in the GIA assay depending on the
concentration used (54), while Favuzza et al. appear to observe an
additive interaction between RH5 and CyRPA mAbs (55). Given
CyRPA, RH5 and Ripr form a complex (56, 57), it is possible
that individual antibody clones that block or stabilize different
aspects of complex formation could mediate either synergistic
or additive interactions with anti-RH5 antibodies. However, the
relationship between antibody potency and the role of the target
antigen protein in merozoite invasion is far from clear: we have
previously found that antibodies to RH5 interact synergistically
with antibodies to RH2, RH4, and EBA175, additively with
antibodies to MSP1 and sub-additively with antibodies to AMA1
(30), none of which are known to interact directly with RH5.
Further characterization of the rabbit anti-CyRPA IgG
indicated that the antigen-specific GIA EC50 is substantially
higher than that of vaccine-induced antibodies to RH5 (30)
and AMA1 (58), and more akin to the levels required when
targetingMSP1 (4). These data would argue against prioritization
of CyRPA over RH5 for inclusion in a single-subunit blood-
stage malaria vaccine. However our results are inconsistent
with recent work published by Bustamante et al., who found
that anti-CyRPA rabbit antibodies are at least as potent as
anti-RH5 antibodies (54). Indeed, the GIA EC50 reported by
Bustamante et al. for total IgG from CyRPA-immunized rabbits
against 3D7 clone parasites is 0.3834 mg/mL. This is more
than 10 times lower than our total IgG GIA EC50 of 5.07
mg/mL, and equivalent to our calculated antigen-specific GIA
EC50. Both studies used very similar immunogens and also the
same contractor for rabbit immunization (Cambridge Research
Biochemicals). The differences in the GIA results could have
arisen from other methodological factors, which could include
GIA assay format and potentially differences in adjuvant selection
and/or immunization regimen. We, and others, have noted
quite marked differences in rabbit immunization studies with
regard to overall endpoint titres raised against protein antigens,
which may easily explain the discrepancy of the results for
total IgG. Moreover, it is wholly possible the immunization
protocols affected the quality of anti-CyRPA IgG induced in
the rabbits, and this would suggest careful monitoring of the
protein formulation and anti-CyRPA IgG quality is warranted in
future studies. Nevertheless, the results in our present study are
concordant with those published by Reddy et al. (41) and in line
with the observation that the most potent anti-CyRPA mAbs yet
described have a GIA EC50 of at least 250µg/mL (55, 59–61); by
contrast, the most potent anti-RH5 mAbs have a GIA EC50 of
∼15µg/mL (62). Taken together, it does appear that total IgG
from RH5-based immunization tends to be more potent than
IgG from CyRPA-based immunization. However, if the epitopes
responsible for synergy between anti-RH5 and anti-CyRPA IgG
could be identified and antibodies robustly elicited against them
in combination, this could form the basis for a more effective
bivalent next-generation blood-stage vaccine.
A final unexpected result from our screen was the failure of
antibodies to both the glycan-ablated or the native version of
SEA-1 to exhibit any GIA. Raj et al. found that SEA-1 antibodies
are associated with protection from clinical malaria, and also
showed that vaccination with PbSEA-1 can protect mice from
P. berghei rodent malaria (40). Our results do not necessarily
contradict these findings, because protection from malaria by
anti-SEA-1 antibodies might well be mediated by Fc-dependent
immune effector functions not measured in the GIA assay such
as complement fixation andmyeloid cell activation. However, our
finding that anti-SEA-1 antibodies did not have GIA does conflict
with Raj et al.’s finding that anti-SEA-1 serum antibodies, as well
as mAbs, can block growth in in vitro cultures (40). It is possible
that our protein was not folded correctly, or was insufficiently
immunogenic when immunized into mice with AddaVaxTM
as an adjuvant, leading to a negative result. Fortunately Raj
et al. produced mAbs to SEA-1 (40), and testing these in the
standardized assay of GIA as operated by the International GIA
Reference Laboratory should resolve this discrepancy.
With respect to the process used to select the
“bioinformatically selected panel” of 40 proteins, even in
retrospect it is difficult to say whether the approach taken was
optimal. Of the 15 literature-selected proteins, 8 would have
been identified with the bioinformatic selection algorithm.
Among the 2 robust hits from the screen, CyRPA would have
been selected using the bioinformatic approach whereas S-
antigen would not have (Table S1). This result does suggest
that there may be other invasion-blocking candidate antigens
which were not identified as part of the “Merozoite invasion
sub-network” by Hu et al. (18). It is difficult to say whether our
decision to prioritize the moderately polymorphic proteins at
the expense of non-polymorphic proteins was the right one.
CyRPA and S-antigens, the two robust hits from this study,
both came from the literature-selected panel. CyRPA has one
SNP of >10% prevalence, which would mean that had it been
in the ’bioinformatically-selected’ panel it would have been
brought forward whether we selected the 40 most polymorphic
or the 40 least prevalent genes. S-antigen is so polymorphic
that with the data available at the time it was not possible to
actually count SNPs, and even with data available now a full
discussion of polymorphism in S-antigen is beyond the scope
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of this paper. Both of these antigens elicit antibodies capable
of neutralizing 3D7 and FVO, which differ markedley in their
S-antigen sequences, suggesting that polymorphism is not always
predictive of strain-specific neutralization.
While this study has focused on the assay of GIA, as one
defined mechanistic correlate that is causative of protection
against blood-stage P. falciparum (63) it should be recognized
that alternative assays of anti-merozoite antibody efficacy do
exist, including phagocytosis assays (64), the assay of antibody-
dependent respiratory burst (65), and the assay of antibody-
dependent cellular inhibition (66). Antibody performance in each
of these assays has been shown to correlate with protection from
clinical malaria in the context of naturally-acquired humoral
immunity. However, there are technical challenges with using
these assays for antibodies derived from different species as in
this study. We selected the assay of GIA because our goal was
to benchmark against antibodies to RH5, which are functional in
this assay.
In summary, no antibody specificity in this study
outperformed anti-RH5 antibodies in the GIA assay. Neither
did any polyclonal antibody specificity robustly synergize
with or enhance the GIA of anti-RH5 antibodies, although
additivity with anti-CyRPA IgG was generally consistent.
While we attempted to make this screen as comprehensive
as possible, we were not able to express every candidate
antigen in HEK293 cells, and new antigens continue to be
described that were not included in our original list of proteins.
Bustamante et al. have very recently reported that SERA9,
RAMA, MSRP5, and EBA181 are targets of neutralizing antibody
which potentially synergize with anti-RH5 antibodies (54).
The RH5-interacting protein (Ripr) is another protein with
a strong rationale for testing as a vaccine antigen, but which
has not been well studied due to the difficulty of expressing
it in bacterial and mammalian cell systems (26, 67). It now
remains a priority to test these proteins in human compatible
vaccine-delivery systems to find out if their inclusion in a
multi-valent vaccine offers a realistic possibility of improving on
RH5 alone.
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